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Introduction
The aetiology of Crohn's disease (CD) and ulcerative colitis (UC), the tw o forms of inflammatory bowel disease (IBD), remains as yet unknow n, w hich hampers the development of innovative, custom-made IBD therapies. Existing therapies are often aimed at general mediators or mechanisms of inflammation. Over the past decades, however, knowledge of particular molecular, biochemical and inflammatory events in IBD has increased considerably. New concepts explaining how these events relate to intestinal tissue damage have led to new potentially effective treatment strategies for IBD aimed at counteracting oxidative stress or providing mucosa protection. Some of these therapies were found to have clinical success while others have already been abandoned again, as will be discussed in this short selective review.
Antioxidants
A grow ing body of evidence indicates excessive production of reactive oxygen metabolites (ROMs) as a direct or indirect cause of mucosal tissue damage in IBD (reviewed in Yamada and Grisham 1 ). The principal source of ROMs in IBD are the phagocytic leukocytes. During episodes of inflammation these cells massively infiltrate the intestinal mucosa, where on activation they synthesize and release large amounts of ROMs. Another major ROM producer is the epithelial and endothelial cell-derived enzyme xanthine oxidase. This enzyme is formed and activated after periods of ischaemia and reperfusion, a process implicated in the vasculitis-associated microinfarctions at the intestinal level w hich are thought to contribute to the pathogenesis of IBD, particularly in CD.
The chronic nature of IBD implies an enduring tissue exposure to ROMs. Although the intestinal mucosa contains a wide variety of endogenous antioxidant defence mechanisms, their levels are relatively low compared with those in other organs (e.g. liver, lung). Moreover, the efficacy of these systems may be impaired during inflammation, partly as a result of autooxidation. Thus, IBD mucosa may be in a constant state of oxidative stress, posing a serious threat to intestinal tissue homeostasis.
Interestingly, attenuating oxidative stress has fortuitously already been a therapeutic strategy for almost 50 years. Commonly used drugs in the treatment of IBD, in particular sulphasalazine and its active moiety 5-aminosalicylic acid (5-ASA), were found to be potent ROM scavengers. However, this mechanism is just one of the many pharmacological actions of these agents. It may be clinically relevant to develop therapies specifically aimed at re-balancing the oxidative homeostasis in IBD.
ROM chemistry
The cascade of ROM production (see Fig. 1 
Strategies of antioxidant therapy
In the past decade, a slow ly increasing amount of literature emerged on the evaluation of drug-induced intervention strategies, specifically aimed at prevention or attenuation of intestinal oxidative stress (see Table 1 and Fig. 1 ). Basically, these approaches include inhibition of ROM producing enzymes, direct scavenging of ROMs, or improvement of cellular antioxidant pools. Most investigations, however, used animal models of colitis, w hereas specific antioxidant trials in IBD patient groups are rare.
The principal ROMs involved in tissue damage in IBD or induced colitis in animals have not been defined. Theoretically, the most promising therapeutic antioxidant compounds would be those agents which would decimate the O -2 production, thus aborting the ROM cascade. Production of O -2 can be decreased by administration of allopurinol, an efficient inhibitor of xanthine oxidase. In UC patients, allopurinol has been reported to intensify the efficacy of sulphasalazine/prednisolone regimens, 2 and to prevent or terminate pouchitis. 3 Furthermore, in rats the severity of colonic inflammation induced by acetic acid or mitomycin C was moderately reduced after treatment with allopurinol. 4, 5 Two other xanthine oxidase inhibitors were found to be ineffective, 4 suggesting that xanthine oxidase is not a major ROM source in colitis. The protective effects of allopurinol were explained by its know n intrinsic ability to scavenge O -2 . Indeed, direct O -2 scavenging has proved to be beneficial in several studies. Preliminary studies reported amelioration 6 or even prevention 7 of colitis induction in rodents upon treatment w ith free human SOD. In two preliminary, uncontrolled clinical trials, high positive response rates were observed in patients with severe CD that had been treated w ith free or liposomal-encapsulated bovine copper/zinc SOD. 8, 9 Although these earlier results were encouraging, no further SOD-based clinical trials in IBD patients have been reported for almost 10 years. Conceivably, this may point to certain limitations of the therapeutical applicability of SOD. There have been attempts to increase the enzyme's potential by coupling SOD to carrier molecules to increase its halflife, without affecting its specific activity. However, SOD coupled to polyethyleneglycol or lecithin did not show convincingly better efficacies in the treatment of chemically induced colitis in animals 4, 10 Another serious impediment of SOD therapy may be its poor tissue penetration. Recent research on SOD therapy, therefore, focuses on SOD mimetics w ith a high permeability. A number of these agents (see Table 1 ) have been shown to be beneficial in animal models of
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Mediators of Inflammation · Vol 7 · 1998 159 Table 1 ) have been described that improve histology in acetic acid-or mitomycin C-induced colitis by increasing the availibility of glutathione, the crucial cofactor for glutathione peroxidase. 5, 11, 14 Furthermore, some of the earlier mentioned SOD mimetics also have H 2 O 2 scavenging capabilities.
11,14
Although H 2 O 2 can exist in tissues for a long time and diffuses into all cellular compartments, the deleterious effects of H 2 O 2 are thought to be due to its secondarily derived ROMs OH and HOCl. In UC patients, addition of the potent OH scavenger dimethylsulphoxide (DMSO) to a sulphasalazine/ prednisolone regimen enhanced treatment efficacy. 2 In chemically induced colitis, the evidence does not favour a role for OH so far. Both DMSO and deferoxamine, an iron chelating agent and OH production inhibitor, did not influence inflammation. 4 These findings are in agreement with the view that HOCl rather than OH is involved in ROM mediated tissue damage, particularly in UC. Interestingly, HOCl is able to maintain its levels by inhibition of glutathione peroxidase and catalase. There have been no reports to date on the therapeutical use of specific HOCl scavengers, like ascorbate.
Diet
Malnutrition is common in IBD, and dietary intervention is often a part of IBD therapy (see Burke et a l.) 15 Yet, a role of specific nutrients in manipulating antioxidant status still has to be defined. Dietary components such as a -tocopherol (vitamin E), ascorbate (vitamin C), carotenoids (vitamin A), or glucose have in vitro ROM scavenging capabilities, but reports concerning the beneficial antioxidant actions of these compounds in IBD are very limited.
It has been proposed that some of the SOD mimetics work as carriers of copper.
11 necessary for the synthesis of copper-dependent antioxidants, e.g. SOD. Zinc is an other essential trace metal w ith antioxidant properties, which is a component of antioxidant metalloproteins such as SOD. Zinc deficiencies have been reported in CD, and although supplementation of zinc reduced colitis in rats, 16 it was found to be ineffective in IBD patients. 17 
Mucosa Protectives
The intestinal inflammatory process in IBD not only affects the cells w ithin the lamina propria, but has also a major impact on the function of the epithelial cells of the mucosa. Some therapeutic strategies particularly aim at restoring the epithelial integrity and function, while others are installed to attenuate the mucosal inflammation. In the end, most of the substances appear to do both.
Sucralphate
This non-absorbable aluminium salt of sucrose octasulphate has the capability to selectively bind to damaged and ulcerated tissue, thereby providing protection against noxious agents. Sucralphate is particularly know n from the treatment of upper gastrointestinal inflammation and ulceration, but in several clinical trials attempts were made to assess its efficacy in distal colitis and proctitis (reviewed in Polson and Misiewicz 18 ). Topical application of sucralphate enemas to patients w ith active distal UC was reported to be of variable success. Apparently some benefit may be achieved, i.e. resolution of rectal bleeding and improvement of histological appearance. In general, however, sucralphate seems to be less effective than prednisolone and of limited use in the treatment of distal colitis.
Short chain fatty acids
Access to colonocyte fuels is essential for the epithelial healing process. Short chain fatty acids, such as propionate, acetate, and butyrate, which are produced by bacterial fermentation of complex carbohydrates or oligosaccharide fibres, are preferred nutrients for colonocytes. 15 In UC patients, utilization of particularly butyrate seems to be impaired, presumably not due to deficiencies in the b -oxidation pathway in the intestinal mucosa, but as a result of a high luminal content of sulphate-reducing bacteria, which produce sulphide that interferes in the butyrate-oxidation (see Fig. 1 ).
Application of butyrate has been successfull in the treatment of colorectal neoplasia, because of its ability to reduce hyperproliferation of epithelial cells and to induce their differentiation (see Fig. 1 ). Likewise, treatment of active UC with butyrate enemas has been reported w ith considerable success regarding endoscopic and histologic improvement, without major side effects, 19 although negative results have been reported as well. Many of the studies, however, were preliminary or uncontrolled trials and larger decisive studies are needed. A number of biochemical studies do provide circumstantial evidence, however, that butyrate-related treatment could be of benefit to patients w ith distal colitis. For instance, it has been found to reduce apoptosis of colonocytes, as well as pro-inflammatory cytokine (IL-8) production by epithelial cells and mucosal inflammation, and to increase colonic mucin production, and adhesion molecule (ICAM-I) and HLA class I expression. These phenomena do indicate that butyrate is able to modulate the intestinal inflammatory process. Perhaps (a combination of) a oligosaccharide fibres-rich diet, topical installation of butyrate, and inhibition of bacterial sulphidogenesis might prove to be of clinical benefit in UC, as has to be show n in better controlled clinical studies.
Long chain (n-3) fatty acids
Arachidonic acid metabolites, like prostaglandin PGE 2 and thrombox ane TXA 2 generated by the cyclooxygenase pathway and leukotriene LTB 4 produced by 5-lipoxygenase, are known to contribute to the inflammatory process in IBD. Specific inhibitors of both oxygenases have been found to either aggravate the inflammation in animal models and patients, or to be clinically ineffective. More encouraging results have been obtained by the oral administration of fish oil and evening primrose oil, which replace the long chain n-6 eicosanoid (arachidonic) fatty acids by n-3 eicosapentaenoic/docosahex aenic acids and g -linoleic acid, respectively. These substances compete with the same ox ygenases and finally yield in the production of less potent inflammatory mediators as LTB 5 , which is less chemotactic and activating for neutrophils than LTB 4 , and PGE 1 which inhibits arachidonic acid release (see Fig. 1 ). Besides the numerous biochemical studies which indicate a reduction in the intestinal inflammatory process, the majority of clinical intervention studies revealed a moderate to good response, with endoscopic and histologic improvement and a steroid-sparing effect in UC. 15 The major problem with the substances, however, are the unpleasant taste and the almost unacceptable side-effects as flatulence, diarrhoea, heartburn, etc. Most recently, new enteric-coated preparations have been developed which reduce both the therapeutic dose and the side-effects. This new fish oil preparation was found to significantly reduce the relapse rate of patients with Crohn's disease in remission, as determined in a 1-year controlled study. 20 Although similar studies were found to be less impressive and there was some debate on the fish oil composition and patient inclusion criteria, these results are very promising and need to be expanded by further studies.
Although many aspects of the biochemical mechanisms w hich are elicited by long chain n-3 fatty acids have been elucidated, the exact anti-inflammatory working profile is still unravelled. Apparently, not only a shift takes place towards less harmful prostaglandins and leukotrienes, but there is also compelling evidence that dietary fish oil supplementation is able to directly or indirectly downregulate pro-inflammatory cytokines, like TNF, IL-1 and IL-6
21 (see Fig. 1 ). Furthermore, there are some indications that these dietary lipids are able to improve the antioxidant status of tissues. 22 In that context, one interesting aspect might need some further attention. Many of the long chain n-3 fatty acid preparations contain antioxidants, like vitamin E, to prevent lipid peroxidation of the oils. The contribution of these antioxidants to the attenuation of the inflammatory response might be worthwhile pursuing.
Finally, a recent study with a bacterial cell wall induced colitis in rats showed that a complete enteral diet containing the combination of fish oil and diverse oligosaccharides was as effective as sulphasalazine in improving the chronic intestinal inflammation.
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Conclusion and Perspectives
Although there has been considerable progress in the understanding of metabolic and oxidative processes and how they relate to tissue damage in IBD, their translation into clinical practice has yet to be made. The initial enthusiasm for innovative mucosa protectives and antioxidant agents in IBD therapy has been somewhat tempered, because of the lack of efficacy or of large confirmative controlled clinical trials. At present we may conclude that their position in the therapeutic armament for IBD w ill be, at their best, in the form of adjunctive (dietary) therapy.
